Pharmena

Pharmena ROE

The Return on Equity (ROE) of Pharmena (PHR.WA) as of Oct 16, 2026 is -28.70 %. In the previous year, Return on Equity (ROE) was -10.16 % — a change of 182.45% (lower).

ROE

-28.70 %

YoY

182.45%

Last updated:

In 2025, Pharmena's return on equity (ROE) was -28.70 %, a 182.45% increase from the -10.16 % ROE in the previous year.

The Pharmena ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-22.95 PLN
Jan 1, 2019
-186.32 PLN
Jan 1, 2020
4,957.55 PLN
Jan 1, 2021
94.39 PLN
Jan 1, 2022
24.19 PLN
Jan 1, 2023
128.51 PLN
Jan 1, 2024
-10.16 PLN
Jan 1, 2025
-28.70 PLN
The Pharmena ROE history
YEARROEYoY
-28.70 %+182.45%
-10.16 %-107.91%
128.51 %+431.22%
24.19 %-74.37%
94.39 %-98.10%
4,957.55 %-2,760.81%
-186.32 %+711.99%
-22.95 %-65.80%
-67.09 %+139.61%
-28.00 %-32.85%
-41.70 %+33.52%
-31.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmena Stock analysis

What does Pharmena do? Pharmena SA is a company based in Lodz, Poland, operating within the Consumer Staples sector, specifically in the Consumer products industry. The company has 24 employees and went public on August 25, 2008. Pharmena SA develops and markets products based on a patented active substance called 1-MNA, which is described as physiological and natural. The company's product range includes Dermena, a line targeting hair loss; Dermena Plus, a shampoo designed to reduce dandruff symptoms and prevent excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care; Thermi, a gel for treating thermal burns and sunburns; and Revium, a line of anti-wrinkle treatments. Pharmena SA collaborates with research centers across Europe, the United States, and Canada on multidirectional research and application studies. The company maintains a wholly owned subsidiary, Cortria Corporation, which is based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in Pharmena SA, and Pelion SA is identified as the main shareholder. The company's website is www.pharmena.eu. Pharmena is one of the most popular companies on Eulerpool.

ROE Details

Decoding Pharmena's Return on Equity (ROE)

Pharmena's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pharmena's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pharmena's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pharmena’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pharmena stock

Return on Equity (ROE) of Pharmena is -28.70 % in 2025.

Return on Equity (ROE) of Pharmena changed from -10.16 % to -28.70 %, representing a 182.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Pharmena since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Pharmena with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Pharmena

All Key Metrics — Pharmena